Compare ARDX & JBLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | JBLU |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2014 | N/A |
| Metric | ARDX | JBLU |
|---|---|---|
| Price | $5.78 | $4.71 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 10 | 9 |
| Target Price | ★ $10.65 | $4.76 |
| AVG Volume (30 Days) | 2.7M | ★ 16.9M |
| Earning Date | 10-30-2025 | 01-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $398,234,000.00 | ★ $9,095,000,000.00 |
| Revenue This Year | $22.77 | N/A |
| Revenue Next Year | $28.02 | $8.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 58.12 | N/A |
| 52 Week Low | $3.21 | $3.34 |
| 52 Week High | $6.78 | $8.31 |
| Indicator | ARDX | JBLU |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 49.42 |
| Support Level | $5.63 | $4.72 |
| Resistance Level | $6.04 | $4.99 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 17.31 | 12.26 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.